If LDL remains above 70 mg/dL after maximally tolerated statin therapy and Zetia, which therapy can be considered?

Prepare for the ACCSAP CCKE Coronary Artery Disease Test. Use flashcards and multiple choice questions, complete with hints and explanations. Ensure success on your test!

Multiple Choice

If LDL remains above 70 mg/dL after maximally tolerated statin therapy and Zetia, which therapy can be considered?

Explanation:
When LDL remains above the target despite maximizing statin therapy plus ezetimibe, the next step is to add a PCSK9 inhibitor. These drugs work by blocking PCSK9, which normally reduces LDL receptors on liver cells. With PCSK9 inhibited, more LDL receptors are available to clear LDL cholesterol from the bloodstream, producing a large additional drop in LDL—typically around 50-60% on top of what statins and ezetimibe achieve. This substantial further reduction helps many high-risk patients reach the goal of LDL below 70 mg/dL. PCSK9 inhibitors, such as evolocumab and alirocumab, are given by subcutaneous injection every few weeks and have demonstrated cardiovascular outcome benefits in major trials. They are especially appropriate when a patient has not reached LDL targets on maximally tolerated statin therapy with ezetimibe and remains at elevated ASCVD risk. Other options are less favorable in this scenario because they are either less potent at lowering LDL, have tolerability or safety concerns, or wouldn’t provide the needed additional reduction after ezetimibe.

When LDL remains above the target despite maximizing statin therapy plus ezetimibe, the next step is to add a PCSK9 inhibitor. These drugs work by blocking PCSK9, which normally reduces LDL receptors on liver cells. With PCSK9 inhibited, more LDL receptors are available to clear LDL cholesterol from the bloodstream, producing a large additional drop in LDL—typically around 50-60% on top of what statins and ezetimibe achieve. This substantial further reduction helps many high-risk patients reach the goal of LDL below 70 mg/dL.

PCSK9 inhibitors, such as evolocumab and alirocumab, are given by subcutaneous injection every few weeks and have demonstrated cardiovascular outcome benefits in major trials. They are especially appropriate when a patient has not reached LDL targets on maximally tolerated statin therapy with ezetimibe and remains at elevated ASCVD risk.

Other options are less favorable in this scenario because they are either less potent at lowering LDL, have tolerability or safety concerns, or wouldn’t provide the needed additional reduction after ezetimibe.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy